Live Breaking News & Updates on Drs Strizki

Stay updated with breaking news from Drs strizki. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial | Infectious Diseases | JAMA

This randomized clinical trial compares the efficacy and safety of letermovir vs valganciclovir prophylaxis for cytomegalovirus (CMV) disease in CMV-seronegativ ....

United States , University Of Washington , San Diego , Ajitp Limaye , Merck Co Inc , Merck Co , European Medicines Agency , American Society Of Nephrology Kidney Week , Gilead Sciences , Merck Sharp Dohme , American Transplant Congress , Drug Administration , Good Clinical Practice , International Conference , Harmonization Guideline , Secondary Efficacy Outcomes , Efficacy Outcomes , Size Calculation , Efficacy Outcome , Interest Disclosures , Viiv Healthcare , Drs Strizki , Merck Sharp , Infectious Disease Week , American Society , Nephrology Kidney Week ,